Lisata Therapeutics, Inc. - Common Stock (LSTA)

0.8989
-0.0111 (-1.22%)
NASDAQ · Last Trade: Nov 21st, 8:12 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.9100
Open0.8827
Bid0.8112
Ask0.9390
Day's Range0.8500 - 0.9000
52 Week Range0.8500 - 5.070
Volume139,293
Market Cap54.41M
PE Ratio (TTM)-0.4781
EPS (TTM)-1.9
Dividend & YieldN/A (N/A)
1 Month Average Volume134,058

Chart

About Lisata Therapeutics, Inc. - Common Stock (LSTA)

Lisata Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies to address unmet medical needs in various disease areas. The company specializes in creating novel treatments that target specific health conditions, with an emphasis on delivering effective solutions to improve patient outcomes. Through rigorous research and development, Lisata aims to advance its pipeline of therapeutic candidates and contribute to the future of healthcare by harnessing the potential of scientific advancements in biotechnology. Read More

News & Press Releases

Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company’s common stock following the reverse stock split will be 128058 401.
By Lisata Therapeutics, Inc. · Via GlobeNewswire · November 19, 2026
Top US Stock Movers in Today's Session: Gainers and Loserschartmill.com
Via Chartmill · November 11, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of
Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL
By Lisata Therapeutics, Inc. · Via GlobeNewswire · November 9, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences:
By Lisata Therapeutics, Inc. · Via GlobeNewswire · November 5, 2026
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 14, 2026
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 8, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 5, 2026
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · October 4, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function
By Lisata Therapeutics, Inc. · Via GlobeNewswire · September 24, 2026
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases
By Lisata Therapeutics, Inc. · Via GlobeNewswire · September 17, 2026
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders
By Lisata Therapeutics, Inc. · Via GlobeNewswire · August 4, 2026
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · July 28, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · July 21, 2026
The market is filled with gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · July 21, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · July 21, 2026
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones
By Lisata Therapeutics, Inc. · Via GlobeNewswire · June 10, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · May 14, 2026
Halper Sadeh LLC is Investigating Whether NSA, LSTA, TALK are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 
By Halper Sadeh LLC · Via GlobeNewswire · May 12, 2026
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 
By Halper Sadeh LLC · Via GlobeNewswire · May 5, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · May 5, 2026
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 
By Halper Sadeh LLC · Via GlobeNewswire · May 4, 2026
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 
By Halper Sadeh LLC · Via GlobeNewswire · March 10, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
By Lisata Therapeutics, Inc. · Via GlobeNewswire · March 6, 2026
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
Shareholders should contact the firm as there may be limited time to enforce your rights
By Halper Sadeh LLC · Via GlobeNewswire · February 2, 2026